This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: August 29, 2007
Last updated: September 16, 2008
Last verified: September 2008
The purpose of this study is to determine whether the improvement in the quality of life after an initial treatment with esomeprazole 40mg for reflux disease is the same in patients who have already made lifestyle-adjustments as in patients who have not implemented lifestyle-adjustments prior to the start of treatment (baseline)

Condition Intervention
GERD Quality of Life Drug: esomeprazole

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Estimated Enrollment: 990
Study Start Date: June 2004
Study Completion Date: March 2008

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with reflux complaints
  • 18 years of age

Exclusion Criteria:

  • Restrictions as mentioned in the registration text
  • H2RA or PPI use in the month prior to inclusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00524251

  Show 54 Study Locations
Sponsors and Collaborators
Study Director: A Sellink, MD AstraZeneca
Study Chair: N van den Berk AstraZeneca
  More Information

Additional Information: Identifier: NCT00524251     History of Changes
Other Study ID Numbers: N11
Study First Received: August 29, 2007
Last Updated: September 16, 2008

Keywords provided by AstraZeneca:
Patients with reflux complaints
quality of life
lifestyle adjustments

Additional relevant MeSH terms:
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 17, 2017